The COVID-19 pandemic has shown us once again the importance of quickly developing and approving the use of innovative drugs. This publication has two recommendations to help ensure that Canadians have quicker access to medications.
New drugs and vaccines likely to increase life expectancy, quality of life and save money, so we should reduce approval delays as much as possible.
Outside of COVID-19, telemedicine is particularly important in remote areas, where patients may otherwise have to travel long distances to see a physician.
Undercutting the profits of drug companies is no way to reward them for their monumental contribution to our well-being.
Governments and charities should purchase vaccines and either donate them or sell them at discounted prices to poorer countries.
As the world watches massive national vaccination campaigns unfold, the direct positive impacts of pharmaceutical innovation on the health and well-being of the population could not be clearer.
Alors que les campagnes de vaccination nationales battent leur plein, les effets positifs de l’innovation pharmaceutique sur la santé et le bien-être de la population ne peuvent être plus clairs.
Nous devrions utiliser les données exhaustives de la RAMQ pour inciter différentes entreprises pharmaceutiques à venir s’établir au Québec ou pour conclure des ententes à l’israélienne.
The Montreal Economic Institute is one of five organizations calling for a timely examination of our collective finances, health care systems, options for economic growth, and more in the free e-book entitled “Life After COVID: What’s next for Canada?”
Do we really want to be deprived of travel in the name of dogmatic egalitarianism?